Quick Answer
Pyxis Oncology, Inc. reported Diluted EPS of $1.28 per share (loss) for fiscal year 2025.
Pyxis Oncology, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.28 | +3.0% |
| 2024 | -$1.32 | +28.6% |
| 2023 | -$1.85 | +49.3% |
| 2022 | -$3.65 | +59.2% |
| 2021 | -$8.95 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.35 | +0.0% | -16.7% |
| June 30, 2025 | -$0.30 | -3.4% | +14.3% |
| March 31, 2025 | -$0.35 | -483.3% | +0.0% |
| September 30, 2024 | -$0.35 | +37.5% | -20.7% |
| June 30, 2024 | -$0.29 | +29.3% | -383.3% |
| March 31, 2024 | -$0.06 | +88.9% | +89.3% |
| September 30, 2023 | -$0.56 | +34.1% | -36.6% |
| June 30, 2023 | -$0.41 | +48.1% | +24.1% |
- Pyxis Oncology, Inc. showed an increase of +3.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Pyxis Oncology, Inc.’s diluted eps has grown by 85.7% (from $8.95 per share (loss) to $1.28 per share (loss)).
- The most recent figure is from Pyxis Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: